Skip to main content
Log in

Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice

  • Original Articles
  • Paclitaxel, Taxol, Pharmacokinetics, Mice
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

We defined the pharmacokinetics of paclitaxel after i. v., i. p., p. o., and s. c. administration of 22.5 mg/kg to CD2F1 mice. Additional mice were studied after i. v. bolus dosing at 11.25 mg/kg or 3-h continuous i.v. infusions delivered at 43.24 μg kg−1 min−1. Plasma was sampled between 5 min and 40 h after dosing. Brains, hearts, lungs, livers, kidneys, skeletal muscles, and, where applicable, testicles were sampled after i.v. dosing at 22.5 mg/kg. Liquid-liquid extraction followed by isocratic high-performance liquid chromatography (HPLC) with UV detection was used to determine paclitaxel concentrations in plasma and tissues. After i.v. administration to male mice, paclitaxel clearance (CLtb) was 3.25 ml min−1 kg−1 and the terminal half-life (t 1/2) was 69 min. After i.v. administration to female mice, paclitaxel CLtb was 4.54 ml min−1 kg−1 and the terminalt1/2 was 43 min. The bioavailability of paclitaxel was ∼10%, 0, and 0 after i.p., p.o., and s.c. administration, respectively. Paclitaxel bioavailability after i.p. administration was the same when the drug was delivered in a small volume to mimic the delivery method used to evaluate in vivo antitumor efficacy or when it was delivered in a large volume to simulate clinical protocols using i.p. regional therapy. Paclitaxel was not detected in the plasma of mice after i.p. delivery of the drug as a suspension in Klucel: Tween 80. Pharmacokinetic parameters were similar after i.v. delivery of paclitaxel at 22.5 and 11.25 mg/kg; however, the CLtb calculated in these studies was much lower than that associated with 3-h continuous i.v. infusions. After i.v. administration, paclitaxel was distributed extensively to all tissues but the brain and testicle. These data are useful in interpreting preclinical efficacy studies of paclitaxel and predicting human pharmacokinetics through scaling techniques.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chang A, Kim K, Glick J, Anderson T, Karp D, Johnson D (1993) Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer; the Eastern Cooperative Oncology Group (ECOG) results. J Natl Cancer Inst 85: 388

    Google Scholar 

  2. Collins JM, Zaharko DS, Dedrick RL, Chabner BA (1986) Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73

    Google Scholar 

  3. Collins JM, Grieshaber CK, Chabner BA (1990) Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst 82: 1321

    Google Scholar 

  4. D'Argenio DZ, Schumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Methods Programs Biomed 9: 115

    Google Scholar 

  5. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171

    Google Scholar 

  6. Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748

    Google Scholar 

  7. Ettinger DS, Finklestein DM, Sarma R, Johnson DH (1993) Phase II study of taxol in patients with extensive small cell lung cancer. Proc Am Soc Clin Oncol 12: 329

    Google Scholar 

  8. Forastiere AA, Neuberg D, Taylor SG IV, DeConti R, Adams G (1993) Phase II evaluation of taxol in advanced head and neck cancer. Proc Am Soc Clin Oncol 12: 277

    Google Scholar 

  9. Francis P, Rowinsky E, Hakes T, Schneider J, Barakat R, Curtin J, Jones W, Lewis J Jr, Rubin S, Dunlap V, Phillips M, Almadrones L, Hoskins W, Markman M (1993) Phase I trial of weekly intraperitoneal (ip) taxol in patients (pts) with residual ovarian carcinoma (OC): a GOG study. Proc Am Soc Clin Oncol 12: 257

    Google Scholar 

  10. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in metastatic breast cancer. J Natl Cancer Inst 83: 1797

    Google Scholar 

  11. Investigational Drug Branch, National Cancer Institute (1990) Taxol (NSC 125973) Clinical Brochure. National Cancer Institute, Bethesda, Maryland

    Google Scholar 

  12. Jamis-Dow CA, Klecker RW, Sarosy GA, Reed E, Collins JM (1993) Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33: 48

    Google Scholar 

  13. Kearns C, Gianni L, Vigano L, Giani A, Spriggs D, Tutsch K, Schiller J, Sridhara R, Egorin M (1993) Non-linear pharmacokinetics of taxol in humans. Proc Am Soc Clin Oncol 12: 135

    Google Scholar 

  14. Keung ACF, Kaul S, Pinedo HM, Ten Bokkel-Huinink WW, Beijnen JH (1993) Pharmacokinetics of taxol given by 3-h or 24-h infusion to patients with ovarian carcinoma. Proc Am Soc Clin Oncol 12: 130

    Google Scholar 

  15. Klecker RW, Jamis-Dow CA, Egorin MJ, Erkmen K, Parker RJ, Stevens R, Collins JM (1994) Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion and metabolism of3H-taxol in the Sprague-Dawley rat. Drug Metab Dispos 22: 254

    Google Scholar 

  16. Kris MG, O'Connell JP, Gralla RJ (1986) Phase I trial of taxol given as a 3-hour infusion every 21 days. Cancer Treat Rep 70: 605

    Google Scholar 

  17. Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435

    Google Scholar 

  18. Legha SS, Ring S, Papadouplos N (1990) A phase II trial of taxol in metastatic melanoma. Cancer 65: 2478

    Google Scholar 

  19. Leslie J, Kujawa JM, Eddington N, Egorin M, Eiseman J (1993) Stability problems with taxol in mouse plasma during HPLC analysis. J Pharm Biomed Anal 11: 1349

    Google Scholar 

  20. Manfredi JJ, Horwitz SB (1984) An antimitotic agent with a new mechanism of action. Pharmacol Ther 25: 83

    Google Scholar 

  21. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, Rubin S, Curtin J, Barakat R, Phillips M, Horwotz L, Almadrones L, Hoskins W (1992) Phase I trial of intraperitoneal taxol: a Gynecologic Oncology Group study. J Clin Oncol 10: 1485

    Google Scholar 

  22. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273

    Google Scholar 

  23. Monsarrat B, Mariel E, Cros S, Gares D, Guénard D, Guéritte-Voegelein F, Wright M (1990) Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 18: 895

    Google Scholar 

  24. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK (1993) Phase II study of taxol in patients with untreated non-small cell lung cancer. J Natl Cancer Inst 85: 384

    Google Scholar 

  25. Reichman BS, Seidman AD, Crown JPA, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA, Yao TJ, Klecker R, Jamis-Dow C, Collins J, Quinlivan S, Berkery R, Toomasi F, Canetta R, Fisherman J, Arbuck S, Norton L (1993) Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943

    Google Scholar 

  26. Rocci ML, Jusko WJ (1983) LAGRAN program for area and moments in pharmacokinetic analysis. Comput Methods Programs Biomed 16: 203

    Google Scholar 

  27. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, Donehower RC (1989) Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49: 4640

    Google Scholar 

  28. Rowinsky EK, Cazenave LA, Donehower RC (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247

    Google Scholar 

  29. Rowinsky EK, Gilbert M, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692

    Google Scholar 

  30. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejki BG, Cornblath DR, Donehower RC (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010

    Google Scholar 

  31. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E (1992) Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165

    Google Scholar 

  32. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665

    Google Scholar 

  33. Sonnichsen D, Hurwitz C, Pratt C, Relling M (1993) Clinical pharmacodynamics and saturable pharmacokinetics of taxol in pediatric solid tumor patients. Proc Am Soc Clin Oncol 12: 133

    Google Scholar 

  34. Swenerton K, Eisenhauer E, Bokkel Huinink W ten, Myles J, Mangioni C, Burg M van der, Kerr I, Gianni L, Vermorken J, Buser K, Sadura A, Bacon M, Santabarbara P, Onetto N, Canetta R (1993) Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion: a European-Canadian study coordinated by the NCI Canada Clinical Trials Group. Proc Am Soc Clin Oncol 12: 256

    Google Scholar 

  35. Thigpen T, Blessing J, Ball H, Hummel S, Barret R (1990) Phase II trial of taxol as second-line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 9: 156

    Google Scholar 

  36. Wall ME, Wani MC (1977) Antineoplastic agents from plants. Annu Rev Pharmacol Toxicol 17: 117

    Google Scholar 

  37. Walle T, Kumar GN, McMillan JM, Thornburg KR, Walle UK (1994) Taxol metabolism in rat hepatocytes. Biochem Pharmacol (in press)

  38. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent fromTaxus brevifolia. J Am Chem Soc 93: 2325

    Google Scholar 

  39. Wiernik PH, Schwartz EL, Einzig A (1987) Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232

    Google Scholar 

  40. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486

    Google Scholar 

  41. Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, LaGrange and Spline approximation. J Pharmacokinet Biopharm 6: 79

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported by contract NO1-CM27711 awarded by the National Cancer Institute, DHHS

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eiseman, J.L., Eddington, N.D., Leslie, J. et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother. Pharmacol. 34, 465–471 (1994). https://doi.org/10.1007/BF00685656

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685656

Keywords

Navigation